Shares of Moderna Inc. MRNA dropped 0.31% to $63.94 Tuesday, on what proved to be an all-around favorable trading session for ...

Moderna (MRNA) closed at $63.94 in the latest trading session, marking a -0.31% move from the prior day. This change lagged the S&P 500's 0.25% gain on the day. At the same time, the Dow added 0.2%, ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...